Dual antiplatelet therapy (DAPT) using of acetylsalicylic acid and antagonists of platelet’s P2Y12 receptors is included in standards for treatment of patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI). Clopidogrel, prasugrel, and ticagrelor are the P2Y12 receptor inhibitors used as a component of DAPT. The aim of this review is to determine the most effective and the safest P2Y12 receptor inhibitor for treating patients with an invasive treatment strategy of ACS. The TRITON study compared clopidogrel and pragugrel efficacy and safety had demonstrated a significantly higher efficiency in reducing the risk of reaching the primary endpoint (including cardiovascular death, myocardial infarction and stroke) for prasugrel, but at the same time, the prasugrel group was reliably recorded higher rate of major bleeding. Comparison of the efficacy and safety of clopidogrel and ticagrelor was carried out in the PLATO study, where ticagrelor was shown to be more effective in reducing cardiovascular deaths and myocardial infarction, while the safety of the drugs was comparable. A subsequent ISAR-REACT 5 study proved higher efficacy of prasugrel compared to ticagrelor in reducing the risk of reaching a primary endpoint with comparable safety to the major bleeding risk. Baseline data represents that the most effective drug among P2Y12 receptor inhibitors as a component of DAPT for patients with an invasive treatment strategy is prasugrel, and the safest is clopidogrel, which can be considered in elderly patients.
acute coronary syndrome, dual antiplatelet therapy, clopidogrel, prasugrel, ticagrelor
1. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:574-651.
2. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-2619. doihttps://doi.org/10.1093/eurheartj/ ehu278.
3. Bertrand M.E., Simoons M.L., Fox K.A. Management of acute coronary syndromes in patients presenting without persistens ST-segment elevation. Eur Heart J. 2002;23(23):1809-1840.
4. Niitsu Y., Sugitachi A., Ogawa T. Repeat oral dosing of Prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol. 2008;579(1-3):276-282. doi: https://doi.org/10.1016/j. ejphar.2007.10.005
5. Michelson A.D. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008;28(3):33-38.
6. Sadanandan S., Singh I.M. Clopidogrel: the data, the experience, and the controversies. Am J Cardiovasc Drugs. 2012;12:361-374. doihttps://doi.org/10.2165/11636340- 000000000-00000
7. Steinhubl S., Berger P., Brennan D. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol. 2006;47:939-943.
8. Steinhubl S., Berger P., Mann III J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized control trial. JAMA. 2002;288:2411-2419.
9. Qureshi Z., Hobson A.R. Clopidogrel “resistance”: where are we now? Cardiovasc Ther. 2013;31(1):3-11. doihttps://doi.org/10.1111/j.1755-5922.2011.00296.x.
10. Chen Z.M., Jiang L.X., Chen Y.P. Addition if clopidogrel to aspirin in 45,852 patients with acute myocardial infarction; randomized placebo-controlled trial. Lancet. 2005;366:1607-1621. doihttps://doi.org/10.1016/S0140- 6736(05)67660-X.
11. Kazui M., Nishiya Y., Ishizuka T. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
12. Geisler T., Langer H., Wydymus M. Low response to clopidogrel is associated with cardiovascular outcome after stent coronary implantation. Eur Heart J. 2006;27(20):2420-2425.
13. Mirzaev K.B., Sychev D.A., Andreev D.A. Geneticheskie osnovy rezistentnosti k klopidogrelyu: sovremennoe sostoyanie problemy. Rossiyskiy kardiologicheskiy zhurnal. 2015;10(126):92-98. doi:10.15829/ 1560-4071-2015-10-92-98.
14. Laguta P.S., Panchenko E.P. Mesto prasugre- la sredi drugih ingibitorov Z2N12-receptorov trombocitov. Aterotromboz. 2017;(2):43-52. doihttps://doi.org/10.21518/2307-1109-2017-2-43-52.
15. Rehmel J.L., Eckstein J.A., Farid N.A. Interactions of two major metabolites of Prasugrel, a thienopiridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;24:600-607.
16. Laguta P.S., Karpov Yu.A. Tikagrelor pri ostrom koronarnom sindrome s pod'emom segmen- ta ST na elektrokardiogramme: novye vozmozhnosti primeneniya. Novosti kardiologii, 2018;2:16-24.
17. Jernberg T., Payne S.D. Winters K.J. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166-1173.
18. Wiviott S.D., Braunwald E., McCabe C.H. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001- 2015.
19. Wiviotti S.D., Braunwald E. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST- elevation myocardial infarction (TRITON-TIMI 38): double-blind,randomised controlled trial. Lancet. 2009;373:723-731.
20. Wiviotti S.D., Braunwald E. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON- TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353-1363.
21. Gurbel P.A. Tantry U.S. Prasugrel, a third generation thienopyridine and potent plateley inhibitor. Curr Opin Investig Drugs. 2008;9(3):324-336.
22. Antman E.M., Wiviott S.D. Murphy S.A.Early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028-2033.
23. Wiviott S.D., Antman E., Winters K. Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-3373.
24. Wallentin L., Becker R.C., Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2009;361(11):1045-1057.
25. Cannon C.P., Harrington R.A., James S. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375(9711):283-293. doi:10.1016/ S0140-6736(09)62191-7.
26. Antman E.M., Wiviott S.D., Murphy S.A. Early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 analysis. J Am Coll Cardiol. 2008;51(21):2028-2033.
27. James S.K., Roe M.T., Cannon C.P. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. BMJ. 2011;342:3527.
28. Farid N.A., Smith R.L. Gillespie T.A. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(7):1096-1104.
29. Lindholm D., Varenhorst C., Cannon C.P. Ticagrelor vs. clopidogrel in patients with non-ST- elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083-2093. doihttps://doi.org/10.1093/eurheartj/ ehu16.
30. Erlih A.D. Rezul'taty klinicheskogo issledovaniya PLATO i mesto tikagrelora v lechenii ostrogo koronarnogo sindroma. Kardiosomatika. 2015;6(1):53-59.
31. Watti H., Khagendra D., Henock G.Z. Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies. International Journal of Cardiology. 2017;249:66-72.
32. Murphy S.A., Antman E.M.,Wiviott S.D. Reduction in recurrent cardiovascular events with Prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;29(20):2473-2479.
33. Sch'pke S., Neumann F.-J., Menichelli M. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381:1524-1534. doi:https://doi.org/10.1056/NEJMoa1908973.
34. Cannon C.P., Harrington R.A., James S., Ardissino D., Becker R.C., Emanuelsson H., Husted S., Katus H., Keltai M., Khurmi N.S., Kontny F., Lewis B.S., Steg P.G., Storey R.F., Wojdyla D., Wallentin L. PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283-93.
35. Angiolillo D.J., Rollini F., Storey R.F., Bhatt D.L., James S., Schneider D.J., Sibbing D., So D.Y.F., Trenk D., Alexopoulos D., Gurbel P.A., Hochholzer W., De Luca L., Bonello L., Aradi D., Cuisset T., Tantry U.S., Wang T.Y., Valgimigli M., Waksman R., Mehran R., Montalescot G., Franchi F., Price M.J. International Expert Consensus on switching platelet P2Y 12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955-1975.
